What changed between these versions
A complete substitute amendment. v2 fundamentally restructures the approach to requiring drug labeling to include original manufacturer and supply chain information, shifting the statutory basis from FFDCA Section 502(b) to a new Section 503(i). It introduces specific civil monetary penalties for non-compliance, modifies the definition of 'original manufacturer', and replaces a direct customs exemption with a requirement for inter-agency coordination, while also extending the effective date significantly.
Overview
Extensive changes throughout the bill, constituting a complete rewrite of the operative text. · v2 represents a fundamental restructuring of the legislative approach, clarifying enforcement mechanisms and agency coordination, while retaining the core policy objective of enhanced labeling.
The second version of S. 3788 is a complete substitute amendment, replacing the entirety of the original bill's operative text. While both versions aim to require drug labeling to include original manufacturer and supply chain information, v2 shifts the statutory basis for these requirements from Section 502(b) to a new Section 503(i) of the Federal Food, Drug, and Cosmetic Act. Additionally, v2 introduces a new civil monetary penalty structure for non-compliance, modifies the definition of 'original manufacturer', and replaces a direct customs marking exemption with a mandate for inter-agency coordination between the FDA and U.S. Customs and Border Protection, alongside a significantly extended effective date.
Major additions
This new subsection establishes the core requirements for drug labeling to include original manufacturer and supply chain information for both active pharmaceutical ingredients (APIs) and finished drug products. It details the information required (name, place of business), how it can be provided (directly on label or electronically), and addresses scenarios with multiple API manufacturers. Crucially, it also outlines the effect of noncompliance, explicitly stating that violations are not criminal.
This addition fundamentally re-establishes the legal framework for the bill's central policy. By placing the requirements under FFDCA Section 503 (prohibited acts) rather than Section 502(b) (misbranding), and by explicitly outlining non-criminal civil penalties, it provides a clearer enforcement pathway and limits the scope of potential legal repercussions for non-compliance.
This new paragraph establishes specific civil monetary penalties for non-compliance with the labeling requirements of the new Section 503(i). Penalties can be up to 25 percent of the total value of the drug product lot(s) involved, with the Secretary considering factors like business size, gravity of violation, prior notice, and good faith efforts in determining the penalty.
This addition provides a clear and direct enforcement tool for the new labeling requirements, which was not explicitly detailed in v1. The inclusion of specific penalty considerations aims to ensure fairness and proportionality in enforcement, providing a defined consequence for non-compliance.
This section mandates coordination between the Commissioner of Food and Drugs and the Commissioner of U.S. Customs and Border Protection to address potential administrative burdens, overlap, duplication, or conflict between the bill's requirements and Section 304 of the Tariff Act of 1930 (country of origin marking). It suggests mechanisms like information sharing and joint rulemaking.
This new provision acknowledges and seeks to mitigate potential conflicts or redundancies between domestic drug labeling requirements and international trade regulations, which could otherwise create significant compliance challenges for manufacturers. It shifts from a direct exemption to a collaborative approach.
This section clarifies that nothing in the Act authorizes the Secretary of Health and Human Services to disclose trade secrets or confidential information protected under federal law, specifically referencing section 552(b)(4) of title 5 and section 1905 of title 18, United States Code.
This addition provides explicit protection for proprietary business information, which is crucial for pharmaceutical manufacturers who must disclose sensitive supply chain data. It aims to address industry concerns regarding data security and competitive intelligence by safeguarding sensitive commercial information.
This section sets the effective date for the amendments made by the Act, stipulating that they shall apply to active pharmaceutical ingredients and finished drug products manufactured and packaged on or after the date that is 5 years after the date of enactment.
This provides a significantly longer implementation timeline compared to v1, giving manufacturers substantially more time to adapt their labeling and supply chain reporting systems to comply with the new requirements. This extended period allows for more thorough preparation and less disruption.
Deletions
This entire section in v1 detailed the amendments to FFDCA Section 502(b), which governs misbranding. It outlined the specific requirements for including manufacturer and supply chain information on drug labels, including unique facility identifiers, electronic access options, paper copy availability, and a definition of 'original manufacturer.'
The deletion of this section means that the core labeling requirements are no longer tied to the misbranding provisions of FFDCA Section 502(b). This represents a fundamental shift in the legal framework and enforcement mechanism for the bill's central policy, as v2 establishes these requirements under a new FFDCA Section 503(i) with distinct penalty provisions.
This section in v1 would have added a new subsection (m) to Section 304 of the Tariff Act of 1930, directly exempting finished drug products marked in accordance with FFDCA Section 502(b)(2)(A) from customs country of origin marking requirements.
The deletion removes a direct statutory exemption from customs marking requirements. Instead, v2 introduces a new Section 4 that mandates coordination between the FDA and U.S. Customs and Border Protection to address potential overlaps or conflicts, indicating a shift from a blanket exemption to a collaborative approach for managing these regulatory interactions.
Modifications
This change could broaden or clarify which entity is considered the 'original manufacturer.' The v1 definition emphasized the final step before interstate commerce, while v2 focuses on the majority of significant manufacturing phases, potentially shifting the identification to an earlier or more central point in the production process, which could impact compliance for manufacturers and the information provided to consumers.
Before
Defined 'original manufacturer' as 'the single last establishment to conduct substantial manufacturing activities prior to introduction of the active pharmaceutical ingredient or finished drug product into interstate commerce.'
After
Defines 'original manufacturer' as 'the establishment that conducts the majority of the significant phases of manufacturing (chemical, physical, or biological manipulation) to produce the active pharmaceutical ingredient or the finished dosage form.'
Scope
Complete substitute — Changes are scattered throughout the bill, as the entire original text has been replaced with new provisions and a new structure. — While the core policy objective of requiring manufacturer and supply chain information on drug labels remains, v2 represents a meaningful change in the approach to achieving this, particularly regarding enforcement, penalties, and inter-agency coordination. — The changes in v2 introduce new provisions in FFDCA Section 503 and Section 303(f), directly impacting the enforcement and regulatory framework for drug labeling. It also replaces the direct interaction with the Tariff Act in v1 with a mandate for agency coordination, creating new inter-agency responsibilities.
Impact analysis
Drug manufacturers, packers, and distributors
Procedural change with clarified enforcement, a potentially different standard for identifying the 'original manufacturer', and a longer compliance window.
V2 shifts the statutory basis for labeling requirements from FFDCA Section 502(b) (misbranding) to a new Section 503(i) (prohibited acts) and introduces specific civil monetary penalties for non-compliance, explicitly stating violations are not criminal. The definition of 'original manufacturer' is also modified, and the effective date is significantly extended.
Consumers and patients
Delayed access to information.
The core intent to provide original manufacturer and supply chain information remains. However, v2's significantly longer effective date means consumers will wait an additional four years (total of five years post-enactment) to see these changes implemented.
U.S. Customs and Border Protection
Increased inter-agency responsibility and potential for new collaborative processes regarding drug import regulations.
V1 would have directly exempted certain finished drug products from customs country of origin marking requirements. V2 removes this direct exemption and instead mandates coordination with the FDA to address potential overlaps or conflicts, including information sharing and joint rulemaking.